High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients

Clinical Microbiology and Infection

Volumn 12, Issue 1, 2006, Pages 56-62

  Goethaert, K ^a   Van Looveren, M ^b   Lammens, C ^b   Jansens, H ^a   Baraniak, A ^c   Gniadkowski, M ^c   Van Herck, K ^b   Jorens, P G ^a   Demey, H E ^a   Ieven, M ^a   Bossaert, L ^a   Goossens, Herman ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Carbapenem; Cefepime; Enterobacter aerogenes; ESBL; Nosocomial infection; TEM 24

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; RIFAMPICIN;

ABDOMINAL INFECTION; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; ENTEROBACTER AEROGENES; ENTEROBACTER INFECTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MEDIASTINITIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SCORING SYSTEM; SEPSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; URINARY TRACT INFECTION;

ENTEROBACTER AEROGENES;

EID: 33644871396     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01290.x     Document Type: Article

References (29)

1. Kliebe C, Nies BA, Meyer JF, Neuzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28: 302-307.
2. Knothe H, Shah P, Kromery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-317.
3. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterisation, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
4. Neuwirth C, Siebor E, Lopez J, Pechinot A, Kazmierczak A. Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum β-lactamase to other members of the family Enterobacteriaceae. J Clin Microbiol 1996; 34: 76-79.
5. Pitout JDD, Thomson KS, Hanson ND, Ehrardt AF, Coudron P, Sanders CC. Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother 1998; 42: 596-600.
6. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463.
7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Cont 1988; 16: 128-140.
8. Vercauteren E, Descheemaeker P, Ieven M, Sanders CC, Goossens H. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol 1997; 42: 2191-2197.
9. Knauss WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II. a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
10. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A5. Wayne, PA: NCCLS, 2000.
11. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol 1995; 26: 2233-2239.
12. Gniadkowski M, I. Schneider R, Jungwirth W, Hryniewicz A, Bauernfeind. Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals. identification of three novel TEM- and SHV-5 type extended spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42: 514-520.
13. Bauernfeind A, Casellas JM, Goldberg M et al. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection 1992; 20: 158-163.
14. Fiett J, Palucha A, Miaczynska B et al. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing Klebsiella. Antimicrob Agents Chemother 2000; 44: 1499-1505.
15. Spapen H, Damas P, Orio VD et al. Consensus statement on the treatment of septic shock. Acta Clin Belg 1999; 54: 256-262.
16. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp. Report from the SENTRY antimicrobial surveillance program. Int J Antimicrob Agents 2003; 21: 1-7.
17. Sanders CC. In vitro activity of fourth generation cephalosporins against Enterobacteriaceae producing extended-spectrum β-lactamases. J Chemother 1996; 8 (suppl 2): 57-62.
18. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-3554.
19. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41: 1053-1057.
20. Paterson DL, Ko W-C, von Gottberg A. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
21. Sanders, WE, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23: 454-461.
22. Mimoz O, Jacolot A, Leotard S et al. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains. Antimicrob Agents Chemother 1998; 42: 3304-3308.
23. Chanal CM, Sirot DL, Petit A et al. Multiplicity of TEM-derived β-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids. Antimicrob Agents Chemother 1989; 33: 1915.
24. De Champs C, Sirot D, Chanal C, Poupart MC, Dumas MP, Sirot J. Concomitant dissemination of three extended-spectrum β-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother 1991; 27: 441-457.
25. Chanal C, Sirot D, Romaszko JP, Bret L, Sirot J. Survey of prevalence of extended-spectrum β-lactamases among Enterobacteriaceae. J Antimicrob Chemother 1996; 38: 127-32.
26. De Gheldre Y, Struelens MJ, Glupczynski Y et al. National epidemiological surveys of Enterobacter aerogene s in Belgian Hospitals from 1996 to 1998. J Clin Microbiol 2001; 39: 889-896.
27. Salso S, Culebras E, Andrade R, Picazo JJ. Outbreak of TEM-24 producing Enterobacter aerogenes in a Spanish hospital. Microb Drug Resist 2003; 9: 299-305.
28. Nüesch-Inderbinen MT, Kayser FH. Hächler. Survey and molecular genetics of SHV β-lactamase in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob Agents Chemother 1997, 41: 943-949.
29. Perilli M, Dell'Amico E, Segatore B et al. Molecular characterisation of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nation-wide survey. J Clin Microbiol 2002; 40: 611-614.